Inhibitory effects of some schiff bases and metal complexes on xanthine oxidase
Keywords:
schiff bases, metal complexes, xanthine oxidase, inhibitorsAbstract
Gout cancer, diabetes, and metabolic syndrome are all linked to xanthine oxidase deficiency. Schiff Bases and Metal Complexes, a bioactive substance, and its derivates were tested for their ability to inhibit the enzyme xanthine oxidase in the present study. The objective is to create bio-actives with antioxidant potential from Schiff Bases and Metal Complexes. Metal complexes, Schiff bases, hydrazines and natural acids were all employed to produce ester bonds using molecular docking techniques. The compounds' antioxidant and xanthine oxidase inhibitory activities were evaluated. 4-Metoksi S1 derivatives demonstrated a competitive inhibition of XO ability with IC50 value of 6,601 M and 4-Metoksi S1 was identified as the most active derivative. In the binding site of XO, the new 4-metoksi S1 derivatives bind to amino acid residues Leu257, Glu263, Thr262, Gly260, Ser347, Alkyl and Pi-Alkyl (Lys256, Ile353, Val259, Leu305, Ala346, Phe337). Testing for antioxidant capability of all compounds revealed that they were all very effective. Hybridization of Schiff Bases and Metal Complexes 4-metoksi S1 might lead to more potent xanthine oxidase inhibitors via molecular docking.
References
Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. The Journal of Physiology. 2004;555(3):589-606.
Cao H, Pauff JM, Hille R. X-ray crystal structure of a xanthine oxidase complex with the flavonoid inhibitor quercetin. Journal of Natural Products. 2014;77(7):1693-1699.
Elion GB. The quest for a cure. Annual Review of Pharmacology and Toxicology. 1993;33(1):1-25.
Hanwell MD, Curtis DE, Lonie DC, Vandermeersch T, Zurek E, Hutchison GR. Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. Journal of Cheminformatics. 2012;4(1):1-17
Li P, Tian Y, Zhai H, Deng F, Xie M, Zhang X. Study on the activity of non-purine xanthine oxidase inhibitor by 3D-QSAR modeling and molecular docking. Journal of Molecular Structure. 2013;1051:56-65
Klınenberg JR, Goldfınger SE, Seegmıller JE. The effectiveness of the xanthine oxidase inhibitor allopurinol in the treatment of gout. Annals of İnternal Medicine. 1965;62(4):639-647.
Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry. 2009;30(16):2785-2791.
Morikawa Y, Yamamoto T, Higashino K. Distribution and pathophysiologic role of molybdenum-containing enzymes. Histology and Histopathology. 1997;12(2):513-524.
Patel A, Patel A, Patel A, Patel NM. Determination of polyphenols and free radical scavenging activity of Tephrosia purpurea linn leaves (Leguminosae). Pharmacognosy Research. 2010;2(3):152.
Shen L, Ji HF. Insights into the inhibition of xanthine oxidase by curcumin. Bioorganic and Medicinal Chemistry Letters. 2009;19(21):5990-5993.
Rahim F, Zaman K, Taha M, Ullah H, Ghufran M, Wadood A, et al. Synthesis, in vitro alpha-glucosidase inhibitory potential of benzimidazole bearing bis-Schiff bases and their molecular docking study. Bioorganic Chemistry. 2020;94:103394.
Yu KH. Febuxostat: a novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout. Recent Patents on İnflammation and Allergy Drug Discovery. 2007;1(1):69-75.
